Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Jean-Marie Cuillerot, MD

|

By

|

Estimated Read Time:

1 minute
Names & News

Jean-Marie Cuillerot has been appointed Vice President and Global Head of Clinical Development at Agenus, Inc, Lexington, US, overseeing ongoing clinical development of checkpoint targeted antibodies, including AGEN1884 targeting CTLA-4 and INCAGN1876 targeting GITR. Dr. Cuillerot was Global Head of Clinical Development, Immuno-Oncology, and Vice President of Clinical Immunotherapy/ Immuno-Oncology at EMD Serono Research and Development Institute, an affiliate of Merck Serono, and prior to that at Bristol-Myers Squibb.

About the Authors

Share this Article:

Recent Posts

View ILCN Archives

Upcoming Featured Events

View Calendar
View All Featured Events »

Provider Resources